Arena Pharmaceuticals (ARNA +8.2%) ramps higher today as the company moves closer than it's ever been to bringing its obesity drug Belviq to the U.S. market. A notice on the DEA's website says regulators have approved the scheduling of Belviq as a controlled substance. The notice will be published in the Federal Register tomorrow, and Belviq can be sold 30 days after.